PT-141 Chicago — Chicagoland Peptides
PT-141 is a cyclic melanocortin ligand examined in central receptor panels rather than as a peripheral vasodilator probe. CNS signalling assays that score melanocortin subtype engagement are the laboratory context summarised for Chicago research buyers.
Product
Research guides
- PT-141 (Bremelanotide) and Melanocortin Receptor Signalling: A Research OverviewA citation-indexed survey of the published literature on PT-141 (bremelanotide), a synthetic alpha-MSH analogue characterised as an agonist at melanocortin receptors MC3R and MC4R, covering receptor pharmacology, preclinical models, and the human trial record.
- PT-141 (Bremelanotide): What the Published Research ReportsA citation-indexed overview of the published literature on PT-141 (bremelanotide), a cyclic melanocortin receptor agonist peptide, covering receptor structural work in vitro, rodent and hamster mechanistic models, randomized human trials in sexual dysfunction populations, reported adverse-event profiles, and analytical and delivery studies.
Chicagoland Peptides products are Research Use Only ("RUO") and are intended solely for basic research, pharmaceutical research, laboratory experimentation, or the development of new tests — not for diagnosing, treating, curing, or preventing any disease or condition in any patient. These statements have not been evaluated by the U.S. Food and Drug Administration.